Horizon Therapeutics (NASDAQ:HZNP) issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.20, Morningstar.com reports. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The business had revenue of $280.00 million for the quarter, compared to analyst estimates of $238.35 million. During the same quarter last year, the company earned $0.03 EPS. The business’s quarterly revenue was up 25.0% on a year-over-year basis. Horizon Therapeutics updated its FY 2019 guidance to EPS.
HZNP opened at $23.71 on Friday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.68 and a current ratio of 1.74. Horizon Therapeutics has a 12 month low of $15.75 and a 12 month high of $29.44.
Several institutional investors and hedge funds have recently bought and sold shares of HZNP. Daiwa Securities Group Inc. purchased a new stake in shares of Horizon Therapeutics in the first quarter valued at $29,000. Rockefeller Capital Management L.P. purchased a new stake in shares of Horizon Therapeutics in the first quarter valued at $38,000. Manchester Capital Management LLC purchased a new stake in shares of Horizon Therapeutics in the first quarter valued at $41,000. Private Capital Group LLC grew its position in shares of Horizon Therapeutics by 141.5% in the fourth quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,150 shares during the period. Finally, Quadrant Capital Group LLC purchased a new stake in shares of Horizon Therapeutics in the first quarter valued at $53,000. 87.78% of the stock is owned by institutional investors and hedge funds.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: Float
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.